Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Yabao Pharma to Develop Second Ely Lilly Diabetes Candidate in China

publication date: Oct 20, 2015
Yabao Pharma entered a second strategic collaboration with Eli Lilly for China development of a novel diabetes treatment. The latest drug candidate is Lilly's sodium-glucose linked transporter inhibitor (SGLT1), which has completed a Phase I trial in Singapore. Yabao will own China rights to the SGLT1 molecule and will fund its development, though Lilly retains buy-in options to the China program. In July 2014, Lilly and Yabao agreed to co-develop Lilly's glucokinase activator (GKA). More details....

Stock Symbols: (SHA: 600351) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital